12:00 AM
 | 
Feb 02, 2009
 |  BC Week In Review  |  Company News  |  Deals

ZymoGenetics, Novo Nordisk deal

ZymoGenetics reacquired rights to develop and commercialize IL-21 outside North America. The recombinant IL-21 is in Phase II testing to treat...

Read the full 84 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >